Although the anti-angiogenic effects of FAP-targeted CAR-T cells remain incompletely understood, our results demonstrate that targeted elimination of CAFs by FAP CAR-T and particularly FAP/IL-15 CAR-T cells inhibited tumor angiogenesis, as evidenced by reduced CD31 expression, with FAP/IL-15 CAR-T cells showing stronger effects. The gene discussed is PECAM1; the disease is neoplasm.